<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01575808</url>
  </required_header>
  <id_info>
    <org_study_id>VJH11-01</org_study_id>
    <nct_id>NCT01575808</nct_id>
  </id_info>
  <brief_title>Multi-center Study for Stent Graft System for Peripheral Artery</brief_title>
  <acronym>VJH11-01</acronym>
  <official_title>The Utility of GP1101 Relative to Surgical Bypass in the Treatment of Femoral / Popliteal Arterial Symptomatic Peripheral Arterial Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>W.L.Gore &amp; Associates</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>W.L.Gore &amp; Associates</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The utility of GP1101 will be evaluated relative to that of surgical bypass in the treatment
      of Femoral/Popliteal Arterial Symptomatic Peripheral Arterial Disease. Efficacy will be
      measured by comparison to a Surgical Bypass Efficacy Goal, and Invasiveness will be measured
      by comparison to Surgical Bypass data derived from a retrospective study.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Assisted Patency</measure>
    <time_frame>12 months</time_frame>
    <description>Primary Efficacy Endpoint &gt;
&gt; Primary assisted patency at 12 months, defined as hemodynamic evidence by Angiography or ultrasound of flow through a device that had not required a Target Lesion Revascularization (TLR) to restore blood flow after total occlusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Stay</measure>
    <time_frame>Up to discharge</time_frame>
    <description>Duration (in days) of post-procedure hospital stay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Avoidance of General Anesthesia</measure>
    <time_frame>Day 0</time_frame>
    <description>Percentage of study subjects avoiding general anesthesia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Did Not Experience Any Critical Events(Death, Target Vessel Revascularization, Major Amputation of the Target Limb)</measure>
    <time_frame>1 month</time_frame>
    <description>Composite endpoint of all subjects experiencing death, target vessel revascularization and/or a major amputation of the target limb (above transmetatarsals) within one month of the index procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants Not Experiencing an Adverse Event</measure>
    <time_frame>1 month</time_frame>
    <description>% Avoidance of serious adverse events that are device or procedure-related or for which the relationship is unknown</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants Not Experiencing an Adverse Event</measure>
    <time_frame>3 months</time_frame>
    <description>% Avoidance of serious adverse events that are device or procedure-related or for which the relationship is unknown at 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants Not Experiencing an Adverse Event</measure>
    <time_frame>6 months</time_frame>
    <description>% Avoidance of serious adverse events that are device or procedure-related or for which the relationship is unknown</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants Not Experiencing an Adverse Event</measure>
    <time_frame>12 months</time_frame>
    <description>% Avoidance of serious adverse events that are device or procedure-related or for which the relationship is unknown</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants Not Experiencing an Adverse Event</measure>
    <time_frame>24 months</time_frame>
    <description>% Avoidance of serious adverse events that are device or procedure-related or for which the relationship is unknown</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants Not Experiencing an Adverse Event</measure>
    <time_frame>36 months</time_frame>
    <description>% Avoidance of serious adverse events that are device or procedure-related or for which the relationship is unknown</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants Not Experiencing an Adverse Event</measure>
    <time_frame>48 months</time_frame>
    <description>% Avoidance of serious adverse events that are device or procedure-related or for which the relationship is unknown</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Avoidance of Adverse Events</measure>
    <time_frame>60 months</time_frame>
    <description>% Avoidance of serious adverse events that are device or procedure-related or for which the relationship is unknown</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical Success</measure>
    <time_frame>Post-procedure</time_frame>
    <description>Placement of GP1101 with residual stenosis of less than 30%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary Patency</measure>
    <time_frame>1 month</time_frame>
    <description>Hemodynamic blood flow through GP1101 that had not required a target lesion revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary Patency</measure>
    <time_frame>3 months</time_frame>
    <description>Hemodynamic blood flow through GP1101 that had not required a target lesion revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary Patency</measure>
    <time_frame>6 months</time_frame>
    <description>Hemodynamic blood flow through GP1101 that had not required a target lesion revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary Patency</measure>
    <time_frame>12 months</time_frame>
    <description>Hemodynamic blood flow through GP1101 that had not required a target lesion revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary Patency</measure>
    <time_frame>24 months</time_frame>
    <description>Hemodynamic blood flow through GP1101 that had not required a target lesion revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Patency</measure>
    <time_frame>1 month</time_frame>
    <description>No bypass surgery and no occlusion at the target site</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Patency</measure>
    <time_frame>3 months</time_frame>
    <description>No bypass surgery and no occlusion at the target site</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Patency</measure>
    <time_frame>6 months</time_frame>
    <description>No bypass surgery and no occlusion at the target site</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Patency</measure>
    <time_frame>12 months</time_frame>
    <description>No bypass surgery and no occlusion at the target site</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Patency</measure>
    <time_frame>24 months</time_frame>
    <description>No bypass surgery and no occlusion at the target site</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Avoidance of Stent Fracture</measure>
    <time_frame>1 month</time_frame>
    <description>X-ray for stent fracture evaluated by Core Lab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Avoidance of Stent Fracture</measure>
    <time_frame>3 months</time_frame>
    <description>X-ray for stent fracture evaluated by Core Lab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Avoidance of Stent Fracture</measure>
    <time_frame>6 months</time_frame>
    <description>X-ray for stent fracture evaluated by Core Lab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Avoidance of Stent Fracture</measure>
    <time_frame>12 months</time_frame>
    <description>X-ray for stent fracture evaluated by Core Lab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Avoidance of Stent Fracture</measure>
    <time_frame>24 months</time_frame>
    <description>X-ray for stent fracture evaluated by Core Lab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Avoidance of Target Lesion Revascularization</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Avoidance of Target Lesion Revascularization</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Avoidance of Target Lesion Revascularization</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Avoidance of Target Lesion Revascularization</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Avoidance of Target Lesion Revascularization</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Success</measure>
    <time_frame>1 month</time_frame>
    <description>The Rutherford Classification is a system used to score Chronic Limb Ischemia in Peripheral Artery Disease (PAD). The stages follow (higher numbers are worse):
Stage 0 - Asymptomatic Stage 1 - Mild claudication Stage 2 - Moderate claudication Stage 3 - Severe claudication Stage 4 - Rest pain Stage 5 - Ischemic ulceration not exceeding ulcer of the digits of the foot Stage 6 - Severe ischemic ulcers or frank gangrene
The percentage of people improving by at least one stage (moving frm higher number to lower number) is listed in the results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Success</measure>
    <time_frame>3 months</time_frame>
    <description>The Rutherford Classification is a system used to score Chronic Limb Ischemia in Peripheral Artery Disease (PAD). The stages follow (higher numbers are worse):
Stage 0 - Asymptomatic Stage 1 - Mild claudication Stage 2 - Moderate claudication Stage 3 - Severe claudication Stage 4 - Rest pain Stage 5 - Ischemic ulceration not exceeding ulcer of the digits of the foot Stage 6 - Severe ischemic ulcers or frank gangrene
The percentage of people improving by at least one stage (moving frm higher number to lower number) is listed in the results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Success</measure>
    <time_frame>6 months</time_frame>
    <description>The Rutherford Classification is a system used to score Chronic Limb Ischemia in Peripheral Artery Disease (PAD). The stages follow (higher numbers are worse):
Stage 0 - Asymptomatic Stage 1 - Mild claudication Stage 2 - Moderate claudication Stage 3 - Severe claudication Stage 4 - Rest pain Stage 5 - Ischemic ulceration not exceeding ulcer of the digits of the foot Stage 6 - Severe ischemic ulcers or frank gangrene
The percentage of people improving by at least one stage (moving frm higher number to lower number) is listed in the results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Success</measure>
    <time_frame>12 months</time_frame>
    <description>The Rutherford Classification is a system used to score Chronic Limb Ischemia in Peripheral Artery Disease (PAD). The stages follow (higher numbers are worse):
Stage 0 - Asymptomatic Stage 1 - Mild claudication Stage 2 - Moderate claudication Stage 3 - Severe claudication Stage 4 - Rest pain Stage 5 - Ischemic ulceration not exceeding ulcer of the digits of the foot Stage 6 - Severe ischemic ulcers or frank gangrene
The percentage of people improving by at least one stage (moving frm higher number to lower number) is listed in the results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Success</measure>
    <time_frame>24 months</time_frame>
    <description>The Rutherford Classification is a system used to score Chronic Limb Ischemia in Peripheral Artery Disease (PAD). The stages follow (higher numbers are worse):
Stage 0 - Asymptomatic Stage 1 - Mild claudication Stage 2 - Moderate claudication Stage 3 - Severe claudication Stage 4 - Rest pain Stage 5 - Ischemic ulceration not exceeding ulcer of the digits of the foot Stage 6 - Severe ischemic ulcers or frank gangrene
The percentage of people improving by at least one stage (moving frm higher number to lower number) is listed in the results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ankle-Brachial Index From Baseline</measure>
    <time_frame>Baseline and 1, 3, 6, 12, 24 months, change from baseline at 1 month presented</time_frame>
    <description>Ankle-Brachial Index of each time frame (1, 3, 6, 12, 24 months) compared to baseline (pre-procedure),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ankle-Brachial Index From Baseline</measure>
    <time_frame>Baseline and 1, 3, 6, 12, 24 months, change from baseline at 3 months presented</time_frame>
    <description>Ankle-Brachial Index of each time frame (1, 3, 6, 12, 24 months) compared to baseline (pre-procedure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ankle-Brachial Index From Baseline</measure>
    <time_frame>Baseline and 1, 3, 6, 12, 24 months, change from baseline at 6 months presented</time_frame>
    <description>Ankle-Brachial Index of each time frame (1, 3, 6, 12, 24 months) compared to baseline (pre-procedure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ankle-Brachial Index From Baseline</measure>
    <time_frame>Baseline and 1, 3, 6, 12, 24 months, change from baseline at 12 months presented</time_frame>
    <description>Ankle-Brachial Index of each time frame (1, 3, 6, 12, 24 months) compared to baseline (pre-procedure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ankle-Brachial Index From Baseline</measure>
    <time_frame>Baseline and 1, 3, 6, 12, 24 months, change from baseline at 24 months presented</time_frame>
    <description>Ankle-Brachial Index of each time frame (1, 3, 6, 12, 24 months) compared to baseline (pre-procedure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular Quality of Life Questionnaire - VascuQOL</measure>
    <time_frame>1 month</time_frame>
    <description>VascuQOL Score - Higher score reflects a better quality of life(Score range: 1 to 7). This score is composed of &quot;Activity&quot;, &quot;Symptom&quot;, &quot;Pain&quot;, &quot;Emotional&quot; and &quot;Social&quot; scores as subscales. The total score is calculated as the average value of all scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular Quality of Life Questionnaire - VascuQOL</measure>
    <time_frame>3 months</time_frame>
    <description>VascuQOL Score - Higher score reflects a better quality of life(Score range: 1 to 7). This score is composed of &quot;Activity&quot;, &quot;Symptom&quot;, &quot;Pain&quot;, &quot;Emotional&quot; and &quot;Social&quot; scores as subscales. The total score is calculated as the average value of all scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular Quality of Life Questionnaire - VascuQOL</measure>
    <time_frame>6 months</time_frame>
    <description>VascuQOL Score - Higher score reflects a better quality of life(Score range: 1 to 7). This score is composed of &quot;Activity&quot;, &quot;Symptom&quot;, &quot;Pain&quot;, &quot;Emotional&quot; and &quot;Social&quot; scores as subscales. The total score is calculated as the average value of all scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular Quality of Life Questionnaire - VascuQOL</measure>
    <time_frame>12 months</time_frame>
    <description>VascuQOL Score - Higher score reflects a better quality of life(Score range: 1 to 7). This score is composed of &quot;Activity&quot;, &quot;Symptom&quot;, &quot;Pain&quot;, &quot;Emotional&quot; and &quot;Social&quot; scores as subscales. The total score is calculated as the average value of all scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular Quality of Life Questionnaire - VascuQOL</measure>
    <time_frame>24 months</time_frame>
    <description>VascuQOL Score - Higher score reflects a better quality of life(Score range: 1 to 7). This score is composed of &quot;Activity&quot;, &quot;Symptom&quot;, &quot;Pain&quot;, &quot;Emotional&quot; and &quot;Social&quot; scores as subscales. The total score is calculated as the average value of all scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walking Impairment Questionnaire-WIQ</measure>
    <time_frame>1 month</time_frame>
    <description>WIQ Distance Score - Higher score reflects a better quality of life（Scores range: 0 to 100.）The difficulty of walking with each specific distance(from walking indoor to 450 meter) is ranked on 0 to 4 and these rank value are converted to score according to the difficulty of walking. The distance score is determained by dividing the total score by greatest score and multiplying by 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walking Impairment Questionnaire-WIQ</measure>
    <time_frame>3 months</time_frame>
    <description>WIQ Distance Score - Higher score reflects a better quality of life（Scores range: 0 to 100.）The difficulty of walking with each specific distance(from walking indoor to 450 meter) is ranked on 0 to 4 and these rank value are converted to score according to the difficulty of walking. The distance score is determained by dividing the total score by greatest score and multiplying by 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walking Impairment Questionnaire-WIQ</measure>
    <time_frame>6 months</time_frame>
    <description>WIQ Distance Score - Higher score reflects a better quality of life（Scores range: 0 to 100.）The difficulty of walking with each specific distance(from walking indoor to 450 meter) is ranked on 0 to 4 and these rank value are converted to score according to the difficulty of walking. The distance score is determained by dividing the total score by greatest score and multiplying by 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walking Impairment Questionnaire-WIQ</measure>
    <time_frame>12 months</time_frame>
    <description>WIQ Distance Score - Higher score reflects a better quality of life（Scores range: 0 to 100.）The difficulty of walking with each specific distance(from walking indoor to 450 meter) is ranked on 0 to 4 and these rank value are converted to score according to the difficulty of walking. The distance score is determained by dividing the total score by greatest score and multiplying by 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walking Impairment Questionnaire-WIQ</measure>
    <time_frame>24 months</time_frame>
    <description>WIQ Distance Score - Higher score reflects a better quality of life（Scores range: 0 to 100.）The difficulty of walking with each specific distance(from walking indoor to 450 meter) is ranked on 0 to 4 and these rank value are converted to score according to the difficulty of walking. The distance score is determained by dividing the total score by greatest score and multiplying by 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Avoidance of Blood Transfusion</measure>
    <time_frame>Post-Procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">133</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>GP1101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prospective data collection: Subjects with occlusive disease of the SFA (Superficial Femoral Artery) implanted with GP1101 covered stent graft</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Retrospective Surgical Bypass Outcomes</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Retrospective data collection (Apr 2012 - Apr 2014) of 68 surgical procedures (performed after Jan 2002) at six Japanese centers used to treat femoral-popliteal artery symptomatic PAD for purposes of establishing the invasiveness control data for hospital stay duration, avoidance of general anesthesia and avoidance of intra-operative transfusion. Eligibility criteria for inclusion werer established to be consistent with the experimental arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GP1101</intervention_name>
    <description>Endovascular stent graft implantation</description>
    <arm_group_label>GP1101</arm_group_label>
    <other_name>Gore VIABAHN Endoprosthesis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Rutherford 2-5 category

          -  Subject has read, understood and signed written informed consent which has been
             reviewed and approved by the Institutional Review Board (IRB).

          -  At least 20 years of age.

          -  Ankle-brachial index (ABI) in the study limb in the non-invasive lower extremity
             arterial studies within 30 days prior to study procedure or at the time of study
             procedure is less than or equal to 0.9, or toe-brachial index (TBI) is less than or
             equal to 0.5.

          -  Male, infertile female, or female of child-bearing potential practicing an acceptable
             method of birth control with a negative pregnancy test within 7 days prior to study
             procedure.

          -  Projected life expectancy of greater than 2 years.

          -  The ability to comply with the study protocol, follow-up requirements and required
             testing.

          -  Surgical bypass candidate

          -  Qualifying lesions by angiography

        Exclusion Criteria:

          -  Untreated flow-limiting aortoiliac disease.

          -  Any previous stenting or surgery in the target vessel(i.e. femoro-popliteal artery).

          -  Vascular access/catheterization in the target or contralateral limb within 30 days of
             study enrollment.

          -  Planned surgery or intervention within 30 days after study procedure.

          -  Femoral artery or popliteal artery aneurysm &gt; 1.5 X healthy adjacent vessel diameter.

          -  Non-atherosclerotic disease resulting in stenosis and/or occlusion (e.g., embolism,
             Buerger's disease, vasculitis).

          -  Severe medical comorbidities (untreated CAD/CHF (Congestive Heart Failure), severe
             COPD (Chronic Obstructive Pulmonary Disease), severe dementia, NYHA (New York Heart
             Association) 3/4, severe hypertension, etc.)

          -  Any medical condition that would preclude post-procedural ambulation or completion of
             study follow-up.

          -  Rutherford 5 patients with active infection.

          -  Serum creatinine &gt;2.5 mg/dL within 30 days prior to study procedure.

          -  Rutherford 6 category in the study or non-study limb or major tissue loss extending
             above the proximal phalanx level.

          -  Rutherford 5 characteristics in non-study limb.

          -  Major distal amputation (above the transmetatarsal) in the study or non-study limb.

          -  Active infection that could adversely impact patient outcomes in the study, or any
             patient with septicemia or bacteremia.

          -  Any previously known coagulation disorder, including hypercoagulability.

          -  Morbid obesity or operative scarring that precludes percutaneous approach

          -  Contraindication to anticoagulation or antiplatelet

          -  Known allergies to stent/stent-graft components, including heparin sensitivity,
             allergy, or previous incidence of heparin-induced thrombocytopenia (HIT) type II.

          -  Current peritoneal or hemodialysis

          -  Participation in another clinical trial (except F/P device clinical trial) up to 3
             months prior to study enrollment.

          -  Enrollment in a F/P device clinical trial within the last 12 months.

          -  Interventional or surgical treatment on arteries distal to the target vessel for this
             study within the past 12 months.

          -  Any other factor identified by the Principal Investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takao Ohki, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jikei Medical University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nagoya University Hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>466-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shinshu University Hospital</name>
      <address>
        <city>Nagano</city>
        <state>Asahi, Matsumoto</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Matsuyama Red Cross Hospital</name>
      <address>
        <city>Matsuyama</city>
        <state>Ehime</state>
        <zip>790-8524</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kokura Memorial Hospital</name>
      <address>
        <city>Kitakyushu</city>
        <state>Fukuoka</state>
        <zip>802-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokeidai Memorial Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-0031</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansai Rousai Hospital</name>
      <address>
        <city>Amagasaki</city>
        <state>Hyogo</state>
        <zip>660-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kobe University Hospital</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>650-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kobe Rosai Hospital</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>651-0053</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hyogo College of Medicine Hospital</name>
      <address>
        <city>Nishinomiya</city>
        <state>Hyogo</state>
        <zip>663-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organaization Kanazawa Medical Center</name>
      <address>
        <city>Kanazawa</city>
        <state>Ishikawa</state>
        <zip>920-8650</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sendai Kousei Hospital</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <zip>980-0873</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kishiwada Tokushukai Hospital</name>
      <address>
        <city>Kishiwada</city>
        <state>Osaka</state>
        <zip>596-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cerebral and Cardiovascular Center</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>565-8565</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nara Medical University Hospital</name>
      <address>
        <city>Nara</city>
        <zip>634-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jikei Medical University Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 9, 2012</study_first_submitted>
  <study_first_submitted_qc>April 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2012</study_first_posted>
  <results_first_submitted>April 7, 2017</results_first_submitted>
  <results_first_submitted_qc>July 26, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">February 8, 2018</results_first_posted>
  <last_update_submitted>July 26, 2017</last_update_submitted>
  <last_update_submitted_qc>July 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Symptomatic PAD</keyword>
  <keyword>Stenosis</keyword>
  <keyword>Occlusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>133 participants were enrolled into the GP1101 arm; 14 were training cases, 16 were excluded by the Case Conference Committee; total participants started was 103. Retrospective Surgical Bypass Outcomes represent historical controls (n=68).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>GP1101</title>
          <description>Subjects with occlusive disease of the SFA (Superficial Femoral Artery) implanted with GP1101 covered stent graft &gt;
&gt; GP1101: Endovascular Device Implantation</description>
        </group>
        <group group_id="P2">
          <title>Retrospective Surgical Bypass Outcomes</title>
          <description>Retrospective data collection (Apr 2012 - Apr 2014) surgical procedures (performed after Jan 2002) at six Japanese centers used to treat femoral-popliteal artery symptomatic PAD for purposes of establishing the invasiveness control data for hospital stay duration, avoidance of general anesthesia and avoidance of intra-operative transfusion. Eligibility criteria for inclusion were established to be consistent with the experimental arm.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="103"/>
                <participants group_id="P2" count="68"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="100">Study ongoing. All 103 assessed for primary invasiveness endpoints,100 for primary efficacy endpoint</participants>
                <participants group_id="P2" count="68"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GP1101</title>
          <description>Prospective data collection: Subjects with occlusive disease of the SFA (Superficial Femoral Artery) implanted with GP1101 covered stent graft</description>
        </group>
        <group group_id="B2">
          <title>Retrospective Surgical Bypass Outcomes</title>
          <description>Retrospective data collection (Apr 2012 - Apr 2014) of 68 surgical procedures (performed after Jan 2002) at six Japanese centers used to treat femoral-popliteal artery symptomatic PAD for purposes of establishing the invasiveness control data for hospital stay duration, avoidance of general anesthesia and avoidance of intra-operative transfusion. Eligibility criteria for inclusion were established to be consistent with the experimental arm.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="103"/>
            <count group_id="B2" value="68"/>
            <count group_id="B3" value="171"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="103"/>
                    <count group_id="B2" value="68"/>
                    <count group_id="B3" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.2" spread="7.0"/>
                    <measurement group_id="B2" value="72.3" spread="8.3"/>
                    <measurement group_id="B3" value="73.4" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="103"/>
                    <count group_id="B2" value="68"/>
                    <count group_id="B3" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="103"/>
                    <count group_id="B2" value="68"/>
                    <count group_id="B3" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <population>Height was not measured in the Retrospective Surgical Bypass Outcomes arm</population>
          <units>centimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="103"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="161.9" spread="8.48"/>
                    <measurement group_id="B3" value="161.9" spread="8.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <population>Weight was not measured in the Retrospective Surgical Bypass Outcomes arm</population>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="103"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.2" spread="10.03"/>
                    <measurement group_id="B3" value="59.2" spread="10.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <description>Body Mass Index</description>
          <population>BMI was not measured in the Retrospective Surgical Bypass Outcomes arm</population>
          <units>kg/㎡</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="103"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.5" spread="2.83"/>
                    <measurement group_id="B3" value="22.5" spread="2.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking History</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="103"/>
                    <count group_id="B2" value="68"/>
                    <count group_id="B3" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Current Smoker</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not a Current Smoker</title>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes Mellitus</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="103"/>
                    <count group_id="B2" value="68"/>
                    <count group_id="B3" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>History of Diabetes Mellitus = Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
                <category>
                  <title>History of Diabetes Mellitus = No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hypertension</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="103"/>
                    <count group_id="B2" value="68"/>
                    <count group_id="B3" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>History of Hypertension = Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="150"/>
                  </measurement_list>
                </category>
                <category>
                  <title>History of Hypertension = No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Dyslipidemia</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="103"/>
                    <count group_id="B2" value="68"/>
                    <count group_id="B3" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>History of Dyslipidemia = Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
                <category>
                  <title>History of Dyslipidemia = No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Carotid Disease</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="103"/>
                    <count group_id="B2" value="68"/>
                    <count group_id="B3" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>History of Carotid Disease = Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>History of Carotid Disease = No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Coronary Artery Disease</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="103"/>
                    <count group_id="B2" value="68"/>
                    <count group_id="B3" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>History of Coronary Artery Disease = Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>History of Coronary Artery Disease = No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Myocardial Infarction</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="103"/>
                    <count group_id="B2" value="68"/>
                    <count group_id="B3" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>History of Myocardial Infarction = Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>History of Myocardial Infarction - No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Congestive Heart Failure</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="103"/>
                    <count group_id="B2" value="68"/>
                    <count group_id="B3" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>History of Congestive Heart Failure = Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>HIstory of Congestive Heart Failure = No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Chronic Obstructive Pulmonary Disease (COPD)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="103"/>
                    <count group_id="B2" value="68"/>
                    <count group_id="B3" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>History of COPD = Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>History of COPD = No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Study Limb</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="103"/>
                    <count group_id="B2" value="68"/>
                    <count group_id="B3" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Right</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Left</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ankle Brachial Index (ABI)</title>
          <population>Eligibility met by TBI for one subject.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="102"/>
                    <count group_id="B2" value="68"/>
                    <count group_id="B3" value="170"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.64" spread="0.12"/>
                    <measurement group_id="B2" value="0.47" spread="0.20"/>
                    <measurement group_id="B3" value="0.57" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Rutherford Category</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="103"/>
                    <count group_id="B2" value="68"/>
                    <count group_id="B3" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Category 0 - Asymptomatic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Category 1 - Mild Claudication</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Category 2 - Moderate Claudication</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Category 3 - Severe Claudication</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="99"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Category 4 - Ischemic Rest Pain</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Category 5 - Minor Tissue Loss</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Category 6- Major Tissue Loss</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Primary Assisted Patency</title>
        <description>Primary Efficacy Endpoint &gt;
&gt; Primary assisted patency at 12 months, defined as hemodynamic evidence by Angiography or ultrasound of flow through a device that had not required a Target Lesion Revascularization (TLR) to restore blood flow after total occlusion</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GP1101</title>
            <description>Subjects with occlusive disease of the SFA (Superficial Femoral Artery) implanted with GP1101 covered stent graft &gt;
&gt; GP1101: Endovascular stent graft implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Assisted Patency</title>
          <description>Primary Efficacy Endpoint &gt;
&gt; Primary assisted patency at 12 months, defined as hemodynamic evidence by Angiography or ultrasound of flow through a device that had not required a Target Lesion Revascularization (TLR) to restore blood flow after total occlusion</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>A literature-based Surgical Bypass Efficacy Goal of 65% was compared to the percentage of subjects maintaining primary assisted patency at 12 months. A one-sided z-test using a Type I error of 5% was performed to test the hypotheses that the 12-month primary assisted patency probability of GP1101 is superior to the SBEG of 65%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>z-test</method>
            <method_desc>One-sided z-test</method_desc>
            <param_type>Percentage</param_type>
            <param_value>91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>86.3</ci_lower_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Duration of Stay</title>
        <description>Duration (in days) of post-procedure hospital stay</description>
        <time_frame>Up to discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GP1101</title>
            <description>Prospective data collection: Subjects with occlusive disease of the SFA (Superficial Femoral Artery) implanted with GP1101 covered stent graft</description>
          </group>
          <group group_id="O2">
            <title>Retrospective Surgical Bypass Outcomes</title>
            <description>Retrospective data collection (Apr 2012 - Apr 2014) of 68 surgical procedures (performed after Jan 2002) at six Japanese centers used to treat femoral-popliteal artery symptomatic PAD for purposes of establishing the invasiveness control data for hospital stay duration, avoidance of general anesthesia and avoidance of intra-operative transfusion. Eligibility criteria for inclusion were established to be consistent with the experimental arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Stay</title>
          <description>Duration (in days) of post-procedure hospital stay</description>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="2" upper_limit="3"/>
                    <measurement group_id="O2" value="12.5" lower_limit="10" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis is that the post-procedure hospital stay duration for GP1101 is superior to the post-procedure hospital stay for the retrospective surgical bypass group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate of Avoidance of General Anesthesia</title>
        <description>Percentage of study subjects avoiding general anesthesia</description>
        <time_frame>Day 0</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GP1101</title>
            <description>Prospective data collection: Subjects with occlusive disease of the SFA (Superficial Femoral Artery) implanted with GP1101 covered stent graft</description>
          </group>
          <group group_id="O2">
            <title>Retrospective Surgical Bypass Outcomes</title>
            <description>Retrospective data collection (Apr 2012 - Apr 2014) of 68 surgical procedures (performed after Jan 2002) at six Japanese centers used to treat femoral-popliteal artery symptomatic PAD for purposes of establishing the invasiveness control data for hospital stay duration, avoidance of general anesthesia and avoidance of intra-operative transfusion. Eligibility criteria for inclusion were established to be consistent with the experimental arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Avoidance of General Anesthesia</title>
          <description>Percentage of study subjects avoiding general anesthesia</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The hypothesis is that the rate of avoidance of general anesthesia for GP1101 is superior to the rate of avoidance of general anesthesis for the retrospective surgical bypass group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Fisher Exact</method>
            <param_type>Percentage</param_type>
            <param_value>100</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96.5</ci_lower_limit>
            <ci_upper_limit>100</ci_upper_limit>
            <estimate_desc>Confidence interval calculated with binomial exact method.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Did Not Experience Any Critical Events(Death, Target Vessel Revascularization, Major Amputation of the Target Limb)</title>
        <description>Composite endpoint of all subjects experiencing death, target vessel revascularization and/or a major amputation of the target limb (above transmetatarsals) within one month of the index procedure.</description>
        <time_frame>1 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GP1101</title>
            <description>Prospective data collection: Subjects with occlusive disease of the SFA (Superficial Femoral Artery) implanted with GP1101 covered stent graft</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Did Not Experience Any Critical Events(Death, Target Vessel Revascularization, Major Amputation of the Target Limb)</title>
          <description>Composite endpoint of all subjects experiencing death, target vessel revascularization and/or a major amputation of the target limb (above transmetatarsals) within one month of the index procedure.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage</param_type>
            <param_value>100</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96.5</ci_lower_limit>
            <ci_upper_limit>100.0</ci_upper_limit>
            <estimate_desc>Confidence intervals calculated using the binomial exact method.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants Not Experiencing an Adverse Event</title>
        <description>% Avoidance of serious adverse events that are device or procedure-related or for which the relationship is unknown</description>
        <time_frame>1 month</time_frame>
        <population>Kaplan-Meier estimate done at end of follow-up visit window</population>
        <group_list>
          <group group_id="O1">
            <title>GP1101</title>
            <description>Prospective data collection: Subjects with occlusive disease of the SFA (Superficial Femoral Artery) implanted with GP1101 covered stent graft &gt;
&gt; GP1101: Endovascular stent graft implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Not Experiencing an Adverse Event</title>
          <description>% Avoidance of serious adverse events that are device or procedure-related or for which the relationship is unknown</description>
          <population>Kaplan-Meier estimate done at end of follow-up visit window</population>
          <units>percent of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.1" lower_limit="91.2" upper_limit="99.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants Not Experiencing an Adverse Event</title>
        <description>% Avoidance of serious adverse events that are device or procedure-related or for which the relationship is unknown at 12 months.</description>
        <time_frame>3 months</time_frame>
        <population>Kaplan-Meier estimate done at end of follow-up visit window</population>
        <group_list>
          <group group_id="O1">
            <title>GP1101</title>
            <description>Prospective data collection: Subjects with occlusive disease of the SFA (Superficial Femoral Artery) implanted with GP1101 covered stent graft &gt;
&gt; GP1101: Endovascular stent graft implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Not Experiencing an Adverse Event</title>
          <description>% Avoidance of serious adverse events that are device or procedure-related or for which the relationship is unknown at 12 months.</description>
          <population>Kaplan-Meier estimate done at end of follow-up visit window</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.1" lower_limit="91.2" upper_limit="99.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants Not Experiencing an Adverse Event</title>
        <description>% Avoidance of serious adverse events that are device or procedure-related or for which the relationship is unknown</description>
        <time_frame>6 months</time_frame>
        <population>Kaplan-Meier estimate done at end of follow-up visit window</population>
        <group_list>
          <group group_id="O1">
            <title>GP1101</title>
            <description>Prospective data collection: Subjects with occlusive disease of the SFA (Superficial Femoral Artery) implanted with GP1101 covered stent graft &gt;
&gt; GP1101: Endovascular stent graft implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Not Experiencing an Adverse Event</title>
          <description>% Avoidance of serious adverse events that are device or procedure-related or for which the relationship is unknown</description>
          <population>Kaplan-Meier estimate done at end of follow-up visit window</population>
          <units>percent of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.1" lower_limit="88.7" upper_limit="97.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants Not Experiencing an Adverse Event</title>
        <description>% Avoidance of serious adverse events that are device or procedure-related or for which the relationship is unknown</description>
        <time_frame>12 months</time_frame>
        <population>Kaplan-Meier estimate done at end of follow-up visit window</population>
        <group_list>
          <group group_id="O1">
            <title>GP1101</title>
            <description>Prospective data collection: Subjects with occlusive disease of the SFA (Superficial Femoral Artery) implanted with GP1101 covered stent graft &gt;
&gt; GP1101: Endovascular stent graft implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Not Experiencing an Adverse Event</title>
          <description>% Avoidance of serious adverse events that are device or procedure-related or for which the relationship is unknown</description>
          <population>Kaplan-Meier estimate done at end of follow-up visit window</population>
          <units>percent of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.9" lower_limit="82.3" upper_limit="95.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants Not Experiencing an Adverse Event</title>
        <description>% Avoidance of serious adverse events that are device or procedure-related or for which the relationship is unknown</description>
        <time_frame>24 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants Not Experiencing an Adverse Event</title>
        <description>% Avoidance of serious adverse events that are device or procedure-related or for which the relationship is unknown</description>
        <time_frame>36 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants Not Experiencing an Adverse Event</title>
        <description>% Avoidance of serious adverse events that are device or procedure-related or for which the relationship is unknown</description>
        <time_frame>48 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Avoidance of Adverse Events</title>
        <description>% Avoidance of serious adverse events that are device or procedure-related or for which the relationship is unknown</description>
        <time_frame>60 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Technical Success</title>
        <description>Placement of GP1101 with residual stenosis of less than 30%</description>
        <time_frame>Post-procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GP1101</title>
            <description>Prospective data collection: Subjects with occlusive disease of the SFA (Superficial Femoral Artery) implanted with GP1101 covered stent graft &gt;
&gt; GP1101: Endovascular stent graft implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Technical Success</title>
          <description>Placement of GP1101 with residual stenosis of less than 30%</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Primary Patency</title>
        <description>Hemodynamic blood flow through GP1101 that had not required a target lesion revascularization</description>
        <time_frame>1 month</time_frame>
        <population>Kaplan-Meier estimate done at end of follow-up visit window</population>
        <group_list>
          <group group_id="O1">
            <title>GP1101</title>
            <description>Prospective data collection: Subjects with occlusive disease of the SFA (Superficial Femoral Artery) implanted with GP1101 covered stent graft &gt;
&gt; GP1101: Endovascular stent graft implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Patency</title>
          <description>Hemodynamic blood flow through GP1101 that had not required a target lesion revascularization</description>
          <population>Kaplan-Meier estimate done at end of follow-up visit window</population>
          <units>Probability of having an event</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.0" lower_limit="93.2" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Primary Patency</title>
        <description>Hemodynamic blood flow through GP1101 that had not required a target lesion revascularization</description>
        <time_frame>3 months</time_frame>
        <population>Kaplan-Meier estimate done at end of follow-up visit window</population>
        <group_list>
          <group group_id="O1">
            <title>GP1101</title>
            <description>Prospective data collection: Subjects with occlusive disease of the SFA (Superficial Femoral Artery) implanted with GP1101 covered stent graft &gt;
&gt; GP1101: Endovascular stent graft implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Patency</title>
          <description>Hemodynamic blood flow through GP1101 that had not required a target lesion revascularization</description>
          <population>Kaplan-Meier estimate done at end of follow-up visit window</population>
          <units>Probability of having an event</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.1" lower_limit="91.2" upper_limit="99.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Primary Patency</title>
        <description>Hemodynamic blood flow through GP1101 that had not required a target lesion revascularization</description>
        <time_frame>6 months</time_frame>
        <population>Kaplan-Meier estimate done at end of follow-up visit window</population>
        <group_list>
          <group group_id="O1">
            <title>GP1101</title>
            <description>Prospective data collection: Subjects with occlusive disease of the SFA (Superficial Femoral Artery) implanted with GP1101 covered stent graft &gt;
&gt; GP1101: Endovascular stent graft implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Patency</title>
          <description>Hemodynamic blood flow through GP1101 that had not required a target lesion revascularization</description>
          <population>Kaplan-Meier estimate done at end of follow-up visit window</population>
          <units>Probability of having an event</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.1" lower_limit="84.8" upper_limit="96.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Primary Patency</title>
        <description>Hemodynamic blood flow through GP1101 that had not required a target lesion revascularization</description>
        <time_frame>12 months</time_frame>
        <population>Kaplan-Meier estimate done at end of follow-up visit window</population>
        <group_list>
          <group group_id="O1">
            <title>GP1101</title>
            <description>Prospective data collection: Subjects with occlusive disease of the SFA (Superficial Femoral Artery) implanted with GP1101 covered stent graft &gt;
&gt; GP1101: Endovascular stent graft implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Patency</title>
          <description>Hemodynamic blood flow through GP1101 that had not required a target lesion revascularization</description>
          <population>Kaplan-Meier estimate done at end of follow-up visit window</population>
          <units>Probability of having an event</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.1" lower_limit="84.8" upper_limit="96.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Primary Patency</title>
        <description>Hemodynamic blood flow through GP1101 that had not required a target lesion revascularization</description>
        <time_frame>24 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Patency</title>
        <description>No bypass surgery and no occlusion at the target site</description>
        <time_frame>1 month</time_frame>
        <population>Kaplan-Meier estimate done at end of follow-up visit window</population>
        <group_list>
          <group group_id="O1">
            <title>GP1101</title>
            <description>Prospective data collection: Subjects with occlusive disease of the SFA (Superficial Femoral Artery) implanted with GP1101 covered stent graft &gt;
&gt; GP1101: Endovascular stent graft implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Patency</title>
          <description>No bypass surgery and no occlusion at the target site</description>
          <population>Kaplan-Meier estimate done at end of follow-up visit window</population>
          <units>Probability of having an event</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.0" lower_limit="93.2" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Patency</title>
        <description>No bypass surgery and no occlusion at the target site</description>
        <time_frame>3 months</time_frame>
        <population>Kaplan-Meier estimate done at end of follow-up visit window</population>
        <group_list>
          <group group_id="O1">
            <title>GP1101</title>
            <description>Prospective data collection: Subjects with occlusive disease of the SFA (Superficial Femoral Artery) implanted with GP1101 covered stent graft &gt;
&gt; GP1101: Endovascular stent graft implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Patency</title>
          <description>No bypass surgery and no occlusion at the target site</description>
          <population>Kaplan-Meier estimate done at end of follow-up visit window</population>
          <units>Probability of having an event</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.0" lower_limit="92.4" upper_limit="99.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Patency</title>
        <description>No bypass surgery and no occlusion at the target site</description>
        <time_frame>6 months</time_frame>
        <population>Kaplan-Meier estimate done at end of follow-up visit window</population>
        <group_list>
          <group group_id="O1">
            <title>GP1101</title>
            <description>Prospective data collection: Subjects with occlusive disease of the SFA (Superficial Femoral Artery) implanted with GP1101 covered stent graft &gt;
&gt; GP1101: Endovascular stent graft implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Patency</title>
          <description>No bypass surgery and no occlusion at the target site</description>
          <population>Kaplan-Meier estimate done at end of follow-up visit window</population>
          <units>Probability of having an event</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.0" lower_limit="92.4" upper_limit="99.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Patency</title>
        <description>No bypass surgery and no occlusion at the target site</description>
        <time_frame>12 months</time_frame>
        <population>Kaplan-Meier estimate done at end of follow-up visit window</population>
        <group_list>
          <group group_id="O1">
            <title>GP1101</title>
            <description>Prospective data collection: Subjects with occlusive disease of the SFA (Superficial Femoral Artery) implanted with GP1101 covered stent graft &gt;
&gt; GP1101: Endovascular stent graft implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Patency</title>
          <description>No bypass surgery and no occlusion at the target site</description>
          <population>Kaplan-Meier estimate done at end of follow-up visit window</population>
          <units>Probability of having an event</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.0" lower_limit="92.4" upper_limit="99.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Patency</title>
        <description>No bypass surgery and no occlusion at the target site</description>
        <time_frame>24 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Avoidance of Stent Fracture</title>
        <description>X-ray for stent fracture evaluated by Core Lab</description>
        <time_frame>1 month</time_frame>
        <population>Kaplan-Meier estimate done at end of follow-up visit window</population>
        <group_list>
          <group group_id="O1">
            <title>GP1101</title>
            <description>Prospective data collection: Subjects with occlusive disease of the SFA (Superficial Femoral Artery) implanted with GP1101 covered stent graft &gt;
&gt; GP1101: Endovascular stent graft implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Avoidance of Stent Fracture</title>
          <description>X-ray for stent fracture evaluated by Core Lab</description>
          <population>Kaplan-Meier estimate done at end of follow-up visit window</population>
          <units>Probability of having an event</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Avoidance of Stent Fracture</title>
        <description>X-ray for stent fracture evaluated by Core Lab</description>
        <time_frame>3 months</time_frame>
        <population>Kaplan-Meier estimate done at end of follow-up visit window</population>
        <group_list>
          <group group_id="O1">
            <title>GP1101</title>
            <description>Prospective data collection: Subjects with occlusive disease of the SFA (Superficial Femoral Artery) implanted with GP1101 covered stent graft &gt;
&gt; GP1101: Endovascular stent graft implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Avoidance of Stent Fracture</title>
          <description>X-ray for stent fracture evaluated by Core Lab</description>
          <population>Kaplan-Meier estimate done at end of follow-up visit window</population>
          <units>Probability of having an event</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Avoidance of Stent Fracture</title>
        <description>X-ray for stent fracture evaluated by Core Lab</description>
        <time_frame>6 months</time_frame>
        <population>Kaplan-Meier estimate done at end of follow-up visit window</population>
        <group_list>
          <group group_id="O1">
            <title>GP1101</title>
            <description>Prospective data collection: Subjects with occlusive disease of the SFA (Superficial Femoral Artery) implanted with GP1101 covered stent graft &gt;
&gt; GP1101: Endovascular stent graft implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Avoidance of Stent Fracture</title>
          <description>X-ray for stent fracture evaluated by Core Lab</description>
          <population>Kaplan-Meier estimate done at end of follow-up visit window</population>
          <units>Probability of having an event</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Avoidance of Stent Fracture</title>
        <description>X-ray for stent fracture evaluated by Core Lab</description>
        <time_frame>12 months</time_frame>
        <population>Kaplan-Meier estimate done at end of follow-up visit window</population>
        <group_list>
          <group group_id="O1">
            <title>GP1101</title>
            <description>Prospective data collection: Subjects with occlusive disease of the SFA (Superficial Femoral Artery) implanted with GP1101 covered stent graft &gt;
&gt; GP1101: Endovascular stent graft implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Avoidance of Stent Fracture</title>
          <description>X-ray for stent fracture evaluated by Core Lab</description>
          <population>Kaplan-Meier estimate done at end of follow-up visit window</population>
          <units>Probability of having an event</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Avoidance of Stent Fracture</title>
        <description>X-ray for stent fracture evaluated by Core Lab</description>
        <time_frame>24 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Avoidance of Target Lesion Revascularization</title>
        <time_frame>1 month</time_frame>
        <population>Kaplan-Meier estimate done at end of follow-up visit window</population>
        <group_list>
          <group group_id="O1">
            <title>GP1101</title>
            <description>Prospective data collection: Subjects with occlusive disease of the SFA (Superficial Femoral Artery) implanted with GP1101 covered stent graft &gt;
&gt; GP1101: Endovascular stent graft implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Avoidance of Target Lesion Revascularization</title>
          <population>Kaplan-Meier estimate done at end of follow-up visit window</population>
          <units>Probability of having an event</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Avoidance of Target Lesion Revascularization</title>
        <time_frame>3 months</time_frame>
        <population>Kaplan-Meier estimate done at end of follow-up visit window</population>
        <group_list>
          <group group_id="O1">
            <title>GP1101</title>
            <description>Prospective data collection: Subjects with occlusive disease of the SFA (Superficial Femoral Artery) implanted with GP1101 covered stent graft &gt;
&gt; GP1101: Endovascular stent graft implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Avoidance of Target Lesion Revascularization</title>
          <population>Kaplan-Meier estimate done at end of follow-up visit window</population>
          <units>Probability of having an event</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.0" lower_limit="93.2" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Avoidance of Target Lesion Revascularization</title>
        <time_frame>6 months</time_frame>
        <population>Kaplan-Meier estimate done at end of follow-up visit window</population>
        <group_list>
          <group group_id="O1">
            <title>GP1101</title>
            <description>Prospective data collection: Subjects with occlusive disease of the SFA (Superficial Femoral Artery) implanted with GP1101 covered stent graft &gt;
&gt; GP1101: Endovascular stent graft implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Avoidance of Target Lesion Revascularization</title>
          <population>Kaplan-Meier estimate done at end of follow-up visit window</population>
          <units>Probability of having an event</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.1" lower_limit="88.6" upper_limit="97.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Avoidance of Target Lesion Revascularization</title>
        <time_frame>12 months</time_frame>
        <population>Kaplan-Meier estimate done at end of follow-up visit window</population>
        <group_list>
          <group group_id="O1">
            <title>GP1101</title>
            <description>Prospective data collection: Subjects with occlusive disease of the SFA (Superficial Femoral Artery) implanted with GP1101 covered stent graft &gt;
&gt; GP1101: Endovascular stent graft implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Avoidance of Target Lesion Revascularization</title>
          <population>Kaplan-Meier estimate done at end of follow-up visit window</population>
          <units>Probability of having an event</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.1" lower_limit="86.1" upper_limit="96.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Avoidance of Target Lesion Revascularization</title>
        <time_frame>24 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Success</title>
        <description>The Rutherford Classification is a system used to score Chronic Limb Ischemia in Peripheral Artery Disease (PAD). The stages follow (higher numbers are worse):
Stage 0 – Asymptomatic Stage 1 – Mild claudication Stage 2 – Moderate claudication Stage 3 – Severe claudication Stage 4 – Rest pain Stage 5 – Ischemic ulceration not exceeding ulcer of the digits of the foot Stage 6 – Severe ischemic ulcers or frank gangrene
The percentage of people improving by at least one stage (moving frm higher number to lower number) is listed in the results.</description>
        <time_frame>1 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GP1101</title>
            <description>Prospective data collection: Subjects with occlusive disease of the SFA (Superficial Femoral Artery) implanted with GP1101 covered stent graft &gt;
&gt; GP1101: Endovascular stent graft implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Success</title>
          <description>The Rutherford Classification is a system used to score Chronic Limb Ischemia in Peripheral Artery Disease (PAD). The stages follow (higher numbers are worse):
Stage 0 – Asymptomatic Stage 1 – Mild claudication Stage 2 – Moderate claudication Stage 3 – Severe claudication Stage 4 – Rest pain Stage 5 – Ischemic ulceration not exceeding ulcer of the digits of the foot Stage 6 – Severe ischemic ulcers or frank gangrene
The percentage of people improving by at least one stage (moving frm higher number to lower number) is listed in the results.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Percentage</param_type>
            <param_value>97.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>91.7</ci_lower_limit>
            <ci_upper_limit>99.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Success</title>
        <description>The Rutherford Classification is a system used to score Chronic Limb Ischemia in Peripheral Artery Disease (PAD). The stages follow (higher numbers are worse):
Stage 0 – Asymptomatic Stage 1 – Mild claudication Stage 2 – Moderate claudication Stage 3 – Severe claudication Stage 4 – Rest pain Stage 5 – Ischemic ulceration not exceeding ulcer of the digits of the foot Stage 6 – Severe ischemic ulcers or frank gangrene
The percentage of people improving by at least one stage (moving frm higher number to lower number) is listed in the results.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GP1101</title>
            <description>Prospective data collection: Subjects with occlusive disease of the SFA (Superficial Femoral Artery) implanted with GP1101 covered stent graft &gt;
&gt; GP1101: Endovascular stent graft implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Success</title>
          <description>The Rutherford Classification is a system used to score Chronic Limb Ischemia in Peripheral Artery Disease (PAD). The stages follow (higher numbers are worse):
Stage 0 – Asymptomatic Stage 1 – Mild claudication Stage 2 – Moderate claudication Stage 3 – Severe claudication Stage 4 – Rest pain Stage 5 – Ischemic ulceration not exceeding ulcer of the digits of the foot Stage 6 – Severe ischemic ulcers or frank gangrene
The percentage of people improving by at least one stage (moving frm higher number to lower number) is listed in the results.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Success</title>
        <description>The Rutherford Classification is a system used to score Chronic Limb Ischemia in Peripheral Artery Disease (PAD). The stages follow (higher numbers are worse):
Stage 0 – Asymptomatic Stage 1 – Mild claudication Stage 2 – Moderate claudication Stage 3 – Severe claudication Stage 4 – Rest pain Stage 5 – Ischemic ulceration not exceeding ulcer of the digits of the foot Stage 6 – Severe ischemic ulcers or frank gangrene
The percentage of people improving by at least one stage (moving frm higher number to lower number) is listed in the results.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GP1101</title>
            <description>Prospective data collection: Subjects with occlusive disease of the SFA (Superficial Femoral Artery) implanted with GP1101 covered stent graft &gt;
&gt; GP1101: Endovascular stent graft implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Success</title>
          <description>The Rutherford Classification is a system used to score Chronic Limb Ischemia in Peripheral Artery Disease (PAD). The stages follow (higher numbers are worse):
Stage 0 – Asymptomatic Stage 1 – Mild claudication Stage 2 – Moderate claudication Stage 3 – Severe claudication Stage 4 – Rest pain Stage 5 – Ischemic ulceration not exceeding ulcer of the digits of the foot Stage 6 – Severe ischemic ulcers or frank gangrene
The percentage of people improving by at least one stage (moving frm higher number to lower number) is listed in the results.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Success</title>
        <description>The Rutherford Classification is a system used to score Chronic Limb Ischemia in Peripheral Artery Disease (PAD). The stages follow (higher numbers are worse):
Stage 0 – Asymptomatic Stage 1 – Mild claudication Stage 2 – Moderate claudication Stage 3 – Severe claudication Stage 4 – Rest pain Stage 5 – Ischemic ulceration not exceeding ulcer of the digits of the foot Stage 6 – Severe ischemic ulcers or frank gangrene
The percentage of people improving by at least one stage (moving frm higher number to lower number) is listed in the results.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GP1101</title>
            <description>Prospective data collection: Subjects with occlusive disease of the SFA (Superficial Femoral Artery) implanted with GP1101 covered stent graft &gt;
&gt; GP1101: Endovascular stent graft implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Success</title>
          <description>The Rutherford Classification is a system used to score Chronic Limb Ischemia in Peripheral Artery Disease (PAD). The stages follow (higher numbers are worse):
Stage 0 – Asymptomatic Stage 1 – Mild claudication Stage 2 – Moderate claudication Stage 3 – Severe claudication Stage 4 – Rest pain Stage 5 – Ischemic ulceration not exceeding ulcer of the digits of the foot Stage 6 – Severe ischemic ulcers or frank gangrene
The percentage of people improving by at least one stage (moving frm higher number to lower number) is listed in the results.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Success</title>
        <description>The Rutherford Classification is a system used to score Chronic Limb Ischemia in Peripheral Artery Disease (PAD). The stages follow (higher numbers are worse):
Stage 0 – Asymptomatic Stage 1 – Mild claudication Stage 2 – Moderate claudication Stage 3 – Severe claudication Stage 4 – Rest pain Stage 5 – Ischemic ulceration not exceeding ulcer of the digits of the foot Stage 6 – Severe ischemic ulcers or frank gangrene
The percentage of people improving by at least one stage (moving frm higher number to lower number) is listed in the results.</description>
        <time_frame>24 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Ankle-Brachial Index From Baseline</title>
        <description>Ankle-Brachial Index of each time frame (1, 3, 6, 12, 24 months) compared to baseline (pre-procedure),</description>
        <time_frame>Baseline and 1, 3, 6, 12, 24 months, change from baseline at 1 month presented</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GP1101</title>
            <description>Prospective data collection: Subjects with occlusive disease of the SFA (Superficial Femoral Artery) implanted with GP1101 covered stent graft &gt;
&gt; GP1101: Endovascular stent graft implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Ankle-Brachial Index From Baseline</title>
          <description>Ankle-Brachial Index of each time frame (1, 3, 6, 12, 24 months) compared to baseline (pre-procedure),</description>
          <units>ABI</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.98" spread="0.118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Ankle-Brachial Index From Baseline</title>
        <description>Ankle-Brachial Index of each time frame (1, 3, 6, 12, 24 months) compared to baseline (pre-procedure)</description>
        <time_frame>Baseline and 1, 3, 6, 12, 24 months, change from baseline at 3 months presented</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GP1101</title>
            <description>Prospective data collection: Subjects with occlusive disease of the SFA (Superficial Femoral Artery) implanted with GP1101 covered stent graft &gt;
&gt; GP1101: Endovascular stent graft implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Ankle-Brachial Index From Baseline</title>
          <description>Ankle-Brachial Index of each time frame (1, 3, 6, 12, 24 months) compared to baseline (pre-procedure)</description>
          <units>ABI</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" spread="0.137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Ankle-Brachial Index From Baseline</title>
        <description>Ankle-Brachial Index of each time frame (1, 3, 6, 12, 24 months) compared to baseline (pre-procedure)</description>
        <time_frame>Baseline and 1, 3, 6, 12, 24 months, change from baseline at 6 months presented</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GP1101</title>
            <description>Prospective data collection: Subjects with occlusive disease of the SFA (Superficial Femoral Artery) implanted with GP1101 covered stent graft &gt;
&gt; GP1101: Endovascular stent graft implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Ankle-Brachial Index From Baseline</title>
          <description>Ankle-Brachial Index of each time frame (1, 3, 6, 12, 24 months) compared to baseline (pre-procedure)</description>
          <units>ABI</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.95" spread="0.137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Ankle-Brachial Index From Baseline</title>
        <description>Ankle-Brachial Index of each time frame (1, 3, 6, 12, 24 months) compared to baseline (pre-procedure)</description>
        <time_frame>Baseline and 1, 3, 6, 12, 24 months, change from baseline at 12 months presented</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GP1101</title>
            <description>Prospective data collection: Subjects with occlusive disease of the SFA (Superficial Femoral Artery) implanted with GP1101 covered stent graft &gt;
&gt; GP1101: Endovascular stent graft implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Ankle-Brachial Index From Baseline</title>
          <description>Ankle-Brachial Index of each time frame (1, 3, 6, 12, 24 months) compared to baseline (pre-procedure)</description>
          <units>ABI</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.94" spread="0.171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Ankle-Brachial Index From Baseline</title>
        <description>Ankle-Brachial Index of each time frame (1, 3, 6, 12, 24 months) compared to baseline (pre-procedure)</description>
        <time_frame>Baseline and 1, 3, 6, 12, 24 months, change from baseline at 24 months presented</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vascular Quality of Life Questionnaire - VascuQOL</title>
        <description>VascuQOL Score - Higher score reflects a better quality of life(Score range: 1 to 7). This score is composed of &quot;Activity&quot;, &quot;Symptom&quot;, &quot;Pain&quot;, &quot;Emotional&quot; and &quot;Social&quot; scores as subscales. The total score is calculated as the average value of all scores.</description>
        <time_frame>1 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GP1101</title>
            <description>Prospective data collection: Subjects with occlusive disease of the SFA (Superficial Femoral Artery) implanted with GP1101 covered stent graft &gt;
&gt; GP1101: Endovascular stent graft implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Vascular Quality of Life Questionnaire - VascuQOL</title>
          <description>VascuQOL Score - Higher score reflects a better quality of life(Score range: 1 to 7). This score is composed of &quot;Activity&quot;, &quot;Symptom&quot;, &quot;Pain&quot;, &quot;Emotional&quot; and &quot;Social&quot; scores as subscales. The total score is calculated as the average value of all scores.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vascular Quality of Life Questionnaire - VascuQOL</title>
        <description>VascuQOL Score - Higher score reflects a better quality of life(Score range: 1 to 7). This score is composed of &quot;Activity&quot;, &quot;Symptom&quot;, &quot;Pain&quot;, &quot;Emotional&quot; and &quot;Social&quot; scores as subscales. The total score is calculated as the average value of all scores.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GP1101</title>
            <description>Prospective data collection: Subjects with occlusive disease of the SFA (Superficial Femoral Artery) implanted with GP1101 covered stent graft &gt;
&gt; GP1101: Endovascular stent graft implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Vascular Quality of Life Questionnaire - VascuQOL</title>
          <description>VascuQOL Score - Higher score reflects a better quality of life(Score range: 1 to 7). This score is composed of &quot;Activity&quot;, &quot;Symptom&quot;, &quot;Pain&quot;, &quot;Emotional&quot; and &quot;Social&quot; scores as subscales. The total score is calculated as the average value of all scores.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vascular Quality of Life Questionnaire - VascuQOL</title>
        <description>VascuQOL Score - Higher score reflects a better quality of life(Score range: 1 to 7). This score is composed of &quot;Activity&quot;, &quot;Symptom&quot;, &quot;Pain&quot;, &quot;Emotional&quot; and &quot;Social&quot; scores as subscales. The total score is calculated as the average value of all scores.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GP1101</title>
            <description>Prospective data collection: Subjects with occlusive disease of the SFA (Superficial Femoral Artery) implanted with GP1101 covered stent graft &gt;
&gt; GP1101: Endovascular stent graft implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Vascular Quality of Life Questionnaire - VascuQOL</title>
          <description>VascuQOL Score - Higher score reflects a better quality of life(Score range: 1 to 7). This score is composed of &quot;Activity&quot;, &quot;Symptom&quot;, &quot;Pain&quot;, &quot;Emotional&quot; and &quot;Social&quot; scores as subscales. The total score is calculated as the average value of all scores.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" spread="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vascular Quality of Life Questionnaire - VascuQOL</title>
        <description>VascuQOL Score - Higher score reflects a better quality of life(Score range: 1 to 7). This score is composed of &quot;Activity&quot;, &quot;Symptom&quot;, &quot;Pain&quot;, &quot;Emotional&quot; and &quot;Social&quot; scores as subscales. The total score is calculated as the average value of all scores.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GP1101</title>
            <description>Prospective data collection: Subjects with occlusive disease of the SFA (Superficial Femoral Artery) implanted with GP1101 covered stent graft &gt;
&gt; GP1101: Endovascular stent graft implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Vascular Quality of Life Questionnaire - VascuQOL</title>
          <description>VascuQOL Score - Higher score reflects a better quality of life(Score range: 1 to 7). This score is composed of &quot;Activity&quot;, &quot;Symptom&quot;, &quot;Pain&quot;, &quot;Emotional&quot; and &quot;Social&quot; scores as subscales. The total score is calculated as the average value of all scores.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vascular Quality of Life Questionnaire - VascuQOL</title>
        <description>VascuQOL Score - Higher score reflects a better quality of life(Score range: 1 to 7). This score is composed of &quot;Activity&quot;, &quot;Symptom&quot;, &quot;Pain&quot;, &quot;Emotional&quot; and &quot;Social&quot; scores as subscales. The total score is calculated as the average value of all scores.</description>
        <time_frame>24 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Walking Impairment Questionnaire-WIQ</title>
        <description>WIQ Distance Score - Higher score reflects a better quality of life（Scores range: 0 to 100.）The difficulty of walking with each specific distance(from walking indoor to 450 meter) is ranked on 0 to 4 and these rank value are converted to score according to the difficulty of walking. The distance score is determained by dividing the total score by greatest score and multiplying by 100.</description>
        <time_frame>1 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GP1101</title>
            <description>Prospective data collection: Subjects with occlusive disease of the SFA (Superficial Femoral Artery) implanted with GP1101 covered stent graft &gt;
&gt; GP1101: Endovascular stent graft implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Walking Impairment Questionnaire-WIQ</title>
          <description>WIQ Distance Score - Higher score reflects a better quality of life（Scores range: 0 to 100.）The difficulty of walking with each specific distance(from walking indoor to 450 meter) is ranked on 0 to 4 and these rank value are converted to score according to the difficulty of walking. The distance score is determained by dividing the total score by greatest score and multiplying by 100.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.9" spread="34.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Walking Impairment Questionnaire-WIQ</title>
        <description>WIQ Distance Score - Higher score reflects a better quality of life（Scores range: 0 to 100.）The difficulty of walking with each specific distance(from walking indoor to 450 meter) is ranked on 0 to 4 and these rank value are converted to score according to the difficulty of walking. The distance score is determained by dividing the total score by greatest score and multiplying by 100.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GP1101</title>
            <description>Prospective data collection: Subjects with occlusive disease of the SFA (Superficial Femoral Artery) implanted with GP1101 covered stent graft &gt;
&gt; GP1101: Endovascular stent graft implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Walking Impairment Questionnaire-WIQ</title>
          <description>WIQ Distance Score - Higher score reflects a better quality of life（Scores range: 0 to 100.）The difficulty of walking with each specific distance(from walking indoor to 450 meter) is ranked on 0 to 4 and these rank value are converted to score according to the difficulty of walking. The distance score is determained by dividing the total score by greatest score and multiplying by 100.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.9" spread="34.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Walking Impairment Questionnaire-WIQ</title>
        <description>WIQ Distance Score - Higher score reflects a better quality of life（Scores range: 0 to 100.）The difficulty of walking with each specific distance(from walking indoor to 450 meter) is ranked on 0 to 4 and these rank value are converted to score according to the difficulty of walking. The distance score is determained by dividing the total score by greatest score and multiplying by 100.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GP1101</title>
            <description>Prospective data collection: Subjects with occlusive disease of the SFA (Superficial Femoral Artery) implanted with GP1101 covered stent graft &gt;
&gt; GP1101: Endovascular stent graft implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Walking Impairment Questionnaire-WIQ</title>
          <description>WIQ Distance Score - Higher score reflects a better quality of life（Scores range: 0 to 100.）The difficulty of walking with each specific distance(from walking indoor to 450 meter) is ranked on 0 to 4 and these rank value are converted to score according to the difficulty of walking. The distance score is determained by dividing the total score by greatest score and multiplying by 100.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.0" spread="34.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Walking Impairment Questionnaire-WIQ</title>
        <description>WIQ Distance Score - Higher score reflects a better quality of life（Scores range: 0 to 100.）The difficulty of walking with each specific distance(from walking indoor to 450 meter) is ranked on 0 to 4 and these rank value are converted to score according to the difficulty of walking. The distance score is determained by dividing the total score by greatest score and multiplying by 100.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GP1101</title>
            <description>Prospective data collection: Subjects with occlusive disease of the SFA (Superficial Femoral Artery) implanted with GP1101 covered stent graft &gt;
&gt; GP1101: Endovascular stent graft implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Walking Impairment Questionnaire-WIQ</title>
          <description>WIQ Distance Score - Higher score reflects a better quality of life（Scores range: 0 to 100.）The difficulty of walking with each specific distance(from walking indoor to 450 meter) is ranked on 0 to 4 and these rank value are converted to score according to the difficulty of walking. The distance score is determained by dividing the total score by greatest score and multiplying by 100.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.0" spread="34.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Walking Impairment Questionnaire-WIQ</title>
        <description>WIQ Distance Score - Higher score reflects a better quality of life（Scores range: 0 to 100.）The difficulty of walking with each specific distance(from walking indoor to 450 meter) is ranked on 0 to 4 and these rank value are converted to score according to the difficulty of walking. The distance score is determained by dividing the total score by greatest score and multiplying by 100.</description>
        <time_frame>24 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Avoidance of Blood Transfusion</title>
        <time_frame>Post-Procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GP1101</title>
            <description>Prospective data collection: Subjects with occlusive disease of the SFA (Superficial Femoral Artery) implanted with GP1101 covered stent graft &gt;
&gt; GP1101: Endovascular stent graft implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Avoidance of Blood Transfusion</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Percentage</param_type>
            <param_value>100</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96.5</ci_lower_limit>
            <ci_upper_limit>100.0</ci_upper_limit>
            <estimate_desc>Confidence Interval calculated with binomial exact method.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse events were systematically reported on Case Report Forms</desc>
      <group_list>
        <group group_id="E1">
          <title>GP1101</title>
          <description>Prospective data collection: Subjects with occlusive disease of the SFA (Superficial Femoral Artery) implanted with GP1101 covered stent graft</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Angina pectoris aggravated</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Anginal attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation paroxysmal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Non-sustained ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Bilateral cataracts</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Cataract aggravated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Left cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Right cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Haemorrhage of digestive tract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Right inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Small intestinal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Arterial stent occlusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Device occlusion</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction to antibiotics</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Influenza A virus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Pulmonary aspergillosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Cataract operation complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Chronic subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Coronary artery restenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>In-stent coronary artery restenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>In-stent peripheral artery restenosis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Malleolar fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Peripheral artery restenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Poisoning by hypnotic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>CRP increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Potassium abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Sugar blood level increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Insulin hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Loss of control of blood sugar</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Large intestine carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of lateral wall of oropharynx</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Syncope vasovagal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure chronic aggravated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Interstitial pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Femoral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Iliac artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Thromboembolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Vascular occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5.0</frequency_threshold>
        <default_vocab>MedDRA Version 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Implant site pain</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Vessel puncture site pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Common cold</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension aggravated</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Takao Ohki</name_or_title>
      <organization>Toyko Jikei University Hospital</organization>
      <phone>81-090-2478-8304</phone>
      <email>takohki@msn.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

